問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Tri-Service General Hospital

Recruiting

List

274Cases

2020-12-31 - 2023-12-31

Phase III

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)

  • Condition/Disease

    Active Psoriatic Arthritis

  • Test Drug

    Tildrakizumab

Participate Sites
9Sites

Recruiting9Sites

2020-12-15 - 2022-06-30

Phase III

A Phase 3, multi-center, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy and safety of sodium oligomannate (GV-971) in treatment of mild to moderate Alzheimer’s disease (GREEN MEMORY: GREen Valley 971 EvaluatioN Memory)

  • Condition/Disease

    Alzheimer’s disease

  • Test Drug

    GV-971

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting1Sites

Terminated1Sites

2021-03-17 - 2025-06-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2020-12-01 - 2022-03-22

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-07-30 - 2025-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-06-01 - 2021-09-28

Phase II

A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    M7824

Participate Sites
5Sites

Recruiting5Sites

2018-12-15 - 2022-09-27

Phase II

An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    M7824

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

沈佳儀
Taipei Veterans General Hospital

Division of Thoracic Medicine

2021-11-15 - 2024-03-15

Phase I

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer

  • Condition/Disease

    Small Cell Lung Carcinoma

  • Test Drug

    AMG 757

Participate Sites
3Sites

Recruiting3Sites

2021-11-01 - 2022-08-29

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-11-01 - 2024-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 21 22 23 24 25 28
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB